Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease

Inflammatory bowel disease (IBD) is a chronic condition which includes ulcerative colitis (UC) and Crohn’s disease (CD), the origins of which are not yet fully understood. Both conditions involve an exacerbated immune response in the intestinal tract, leading to tissue inflammation. Dendritic cells...

ver descrição completa

Detalhes bibliográficos
Autores: Soleto, Irene, Ramírez, Cristina, Gómez, Cristina, Baldan-Martin, Montse, Orejudo, Macarena, Mercado, Jorge, Chaparro Sánchez, María, Pérez Gisbert, Francisco Javier
Tipo de documento: artigo
Data de publicação:2023
País:España
Recursos:Universidad Autónoma de Madrid
Repositório:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglês
OAI Identifier:oai:repositorio.uam.es:10486/709409
Acesso em linha:http://hdl.handle.net/10486/709409
https://dx.doi.org/10.3390/biomedicines11102831
Access Level:Acceso aberto
Palavra-chave:dendritic cell
golimumab
ustekinumab
inflammatory bowel disease
ulcerative colitis
Crohn’s disease
Medicina
id ES_caa7dcc5040b9a2f7cb77158cce2ab20
oai_identifier_str oai:repositorio.uam.es:10486/709409
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel diseaseSoleto, IreneRamírez, CristinaGómez, CristinaBaldan-Martin, MontseOrejudo, MacarenaMercado, JorgeChaparro Sánchez, MaríaPérez Gisbert, Francisco Javierdendritic cellgolimumabustekinumabinflammatory bowel diseaseulcerative colitisCrohn’s diseaseMedicinaInflammatory bowel disease (IBD) is a chronic condition which includes ulcerative colitis (UC) and Crohn’s disease (CD), the origins of which are not yet fully understood. Both conditions involve an exacerbated immune response in the intestinal tract, leading to tissue inflammation. Dendritic cells (DCs) are antigen-presenting cells crucial for maintaining tolerance in the gastrointestinal mucosa. Previous research has indicated that DC recruitment to the intestinal mucosa is more pronounced in individuals with IBD, but the specific mechanisms governing this migration remain unclear. This study aimed to assess the expression of various homing markers and the migratory abilities of circulating DC subsets in response to intestinal chemotactic signals. Additionally, this study examined how golimumab and ustekinumab impact these characteristics in individuals with IBD compared to healthy controls. The findings revealed that a particular subset of DCs known as type 2 conventional DCs (cDC2) displayed a more pronounced migratory profile compared to other DC subsets. Furthermore, the study observed that golimumab and ustekinumab had varying effects on the migratory profile of cDC1 in individuals with CD and UC. While CCL2 did not exert a chemoattractant effect on DC subsets in this patient cohort, treatment with golimumab and ustekinumab enhanced their migratory capacity towards CCL2 and CCL25 while reducing their migration towards MadCam1. In conclusion, this study highlights that cDC2 exhibits a heightened migratory profile towards the gastrointestinal mucosa compared to other DC subsets. This finding could be explored further for the development of new diagnostic biomarkers or the identification of potential immunomodulatory targets in the context of IBDMDPIDepartamento de MedicinaFacultad de Medicina20232023-10-18research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/709409https://dx.doi.org/10.3390/biomedicines11102831reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/7094092026-06-23T12:46:27Z
dc.title.none.fl_str_mv Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease
title Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease
spellingShingle Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease
Soleto, Irene
dendritic cell
golimumab
ustekinumab
inflammatory bowel disease
ulcerative colitis
Crohn’s disease
Medicina
title_short Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease
title_full Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease
title_fullStr Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease
title_full_unstemmed Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease
title_sort Effects of golimumab and ustekinumab on circulating dendritic cell migratory capacity in inflammatory bowel disease
dc.creator.none.fl_str_mv Soleto, Irene
Ramírez, Cristina
Gómez, Cristina
Baldan-Martin, Montse
Orejudo, Macarena
Mercado, Jorge
Chaparro Sánchez, María
Pérez Gisbert, Francisco Javier
author Soleto, Irene
author_facet Soleto, Irene
Ramírez, Cristina
Gómez, Cristina
Baldan-Martin, Montse
Orejudo, Macarena
Mercado, Jorge
Chaparro Sánchez, María
Pérez Gisbert, Francisco Javier
author_role author
author2 Ramírez, Cristina
Gómez, Cristina
Baldan-Martin, Montse
Orejudo, Macarena
Mercado, Jorge
Chaparro Sánchez, María
Pérez Gisbert, Francisco Javier
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Departamento de Medicina
Facultad de Medicina
dc.subject.none.fl_str_mv dendritic cell
golimumab
ustekinumab
inflammatory bowel disease
ulcerative colitis
Crohn’s disease
Medicina
topic dendritic cell
golimumab
ustekinumab
inflammatory bowel disease
ulcerative colitis
Crohn’s disease
Medicina
description Inflammatory bowel disease (IBD) is a chronic condition which includes ulcerative colitis (UC) and Crohn’s disease (CD), the origins of which are not yet fully understood. Both conditions involve an exacerbated immune response in the intestinal tract, leading to tissue inflammation. Dendritic cells (DCs) are antigen-presenting cells crucial for maintaining tolerance in the gastrointestinal mucosa. Previous research has indicated that DC recruitment to the intestinal mucosa is more pronounced in individuals with IBD, but the specific mechanisms governing this migration remain unclear. This study aimed to assess the expression of various homing markers and the migratory abilities of circulating DC subsets in response to intestinal chemotactic signals. Additionally, this study examined how golimumab and ustekinumab impact these characteristics in individuals with IBD compared to healthy controls. The findings revealed that a particular subset of DCs known as type 2 conventional DCs (cDC2) displayed a more pronounced migratory profile compared to other DC subsets. Furthermore, the study observed that golimumab and ustekinumab had varying effects on the migratory profile of cDC1 in individuals with CD and UC. While CCL2 did not exert a chemoattractant effect on DC subsets in this patient cohort, treatment with golimumab and ustekinumab enhanced their migratory capacity towards CCL2 and CCL25 while reducing their migration towards MadCam1. In conclusion, this study highlights that cDC2 exhibits a heightened migratory profile towards the gastrointestinal mucosa compared to other DC subsets. This finding could be explored further for the development of new diagnostic biomarkers or the identification of potential immunomodulatory targets in the context of IBD
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-10-18
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/709409
https://dx.doi.org/10.3390/biomedicines11102831
url http://hdl.handle.net/10486/709409
https://dx.doi.org/10.3390/biomedicines11102831
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419498685071360
score 15,300719